Curis Announces First Five Patients Dosed In TakeAim CLL Study Of Emavusertib With Zanubrutinib; Reaffirms Initial Data In 5-10 Patients In December 2026

Loading news article.

Curis Announces First Five Patients Dosed In TakeAim CLL Study Of Emavusertib With Zanubrutinib; Reaffirms Initial Data In 5-10 Patients In December 2026 | WAPE

Curis Announces First Five Patients Dosed In TakeAim CLL Study Of Emavusertib With Zanubrutinib; Reaffirms Initial Data In 5-10 Patients In December 2026

Article summary

Related companies

Comments —